← brief for 2026-08-27 · Slowing decline

Glycemic Outcomes After Switching from SGLT2 Inhibitors to DPP-4 Inhibitors in Type 2 Diabetes, with a Comparison of Teneligliptin and Other Agents: A Retrospective Cohort Study.

Article C Peer reviewed Observational

Key takeaways

Doctors looked back at records of people with type 2 diabetes who stopped SGLT2 inhibitors, often because of side effects, and switched to DPP-4 inhibitors. The study tracked blood sugar after the switch and compared teneligliptin with other drugs in the same class. This matters for kidney patients because SGLT2 inhibitors are one of the few drugs that protect kidneys, so what happens after stopping them is worth knowing. It is a look-back study, so it shows patterns, not proof that one drug caused a better result.

Who did this work

Lim JY · Song M · Kang YE · Lee JH · Kim HJ · Joung KH · Ku BJ

Source

Article · PubMed, the drug frontier · 2026 Aug 6
https://pubmed.ncbi.nlm.nih.gov/42654409/